178 related articles for article (PubMed ID: 35452074)
1. IFNγR Pathway Mediates CAR T Cell Cytotoxicity Against Solid Tumors.
Cancer Discov; 2022 Jun; 12(6):1408. PubMed ID: 35452074
[TBL] [Abstract][Full Text] [Related]
2. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell therapy for solid tumours.
The Lancet Oncology
Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
[No Abstract] [Full Text] [Related]
4. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
6. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
7. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
Feucht J; Abou-El-Enein M
Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
[No Abstract] [Full Text] [Related]
8. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
9. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
10. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
13. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
14. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
[TBL] [Abstract][Full Text] [Related]
15. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
Lin C; Zhang J
Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of IAPs Enhances CAR T-cell Efficacy.
Michie J; Beavis PA; Freeman AJ; Vervoort SJ; Ramsbottom KM; Narasimhan V; Lelliott EJ; Lalaoui N; Ramsay RG; Johnstone RW; Silke J; Darcy PK; Voskoboinik I; Kearney CJ; Oliaro J
Cancer Immunol Res; 2019 Feb; 7(2):183-192. PubMed ID: 30651288
[TBL] [Abstract][Full Text] [Related]
19. Transcription factors in chimeric antigen receptor T-cell development.
Dai A; Zhang X; Wang X; Liu G; Wang Q; Yu F
Hum Cell; 2024 May; 37(3):571-581. PubMed ID: 38436882
[TBL] [Abstract][Full Text] [Related]
20. Activation-induced cell death in CAR-T cell therapy.
Huan T; Chen D; Liu G; Zhang H; Wang X; Wu Z; Wu Y; Xu Q; Yu F
Hum Cell; 2022 Mar; 35(2):441-447. PubMed ID: 35032297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
